A detailed history of Nisa Investment Advisors, LLC transactions in Axsome Therapeutics, Inc. stock. As of the latest transaction made, Nisa Investment Advisors, LLC holds 947 shares of AXSM stock, worth $75,958. This represents 0.0% of its overall portfolio holdings.

Number of Shares
947
Previous 921 2.82%
Holding current value
$75,958
Previous $73,000 2.74%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 01, 2024

BUY
$69.39 - $97.64 $1,804 - $2,538
26 Added 2.82%
947 $75,000
Q4 2023

Jan 25, 2024

BUY
$57.42 - $83.61 $287 - $418
5 Added 0.55%
921 $73,000
Q2 2023

Aug 11, 2023

BUY
$58.41 - $90.35 $5,256 - $8,131
90 Added 10.9%
916 $65,000
Q3 2022

Nov 07, 2022

SELL
$36.06 - $69.85 $2,235 - $4,330
-62 Reduced 6.98%
826 $37,000
Q2 2022

Aug 03, 2022

BUY
$21.74 - $46.75 $13,043 - $28,050
600 Added 208.33%
888 $34,000
Q1 2022

Apr 29, 2022

SELL
$23.7 - $41.39 $42,423 - $74,088
-1,790 Reduced 86.14%
288 $12,000
Q4 2021

Feb 03, 2022

BUY
$30.7 - $43.36 $48,751 - $68,855
1,588 Added 324.08%
2,078 $57,000
Q3 2021

Oct 18, 2021

SELL
$19.91 - $68.26 $43,423 - $148,875
-2,181 Reduced 81.65%
490 $16,000
Q2 2021

Aug 06, 2021

SELL
$50.63 - $73.5 $12,657 - $18,375
-250 Reduced 8.56%
2,671 $180,000
Q4 2020

Jan 25, 2021

BUY
$66.31 - $86.52 $79,969 - $104,343
1,206 Added 70.32%
2,921 $238,000
Q3 2020

Oct 20, 2020

SELL
$68.34 - $85.84 $54,466 - $68,414
-797 Reduced 31.73%
1,715 $122,000
Q2 2020

Jul 27, 2020

BUY
$49.87 - $98.69 $114,302 - $226,197
2,292 Added 1041.82%
2,512 $207,000
Q1 2020

Apr 17, 2020

SELL
$41.2 - $101.31 $3,296 - $8,104
-80 Reduced 26.67%
220 $13,000
Q3 2019

Oct 17, 2019

BUY
$20.24 - $29.16 $6,071 - $8,748
300 New
300 $6,000

Others Institutions Holding AXSM

About Axsome Therapeutics, Inc.


  • Ticker AXSM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,878,000
  • Market Cap $3.44B
  • Description
  • Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...
More about AXSM
Track This Portfolio

Track Nisa Investment Advisors, LLC Portfolio

Follow Nisa Investment Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nisa Investment Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nisa Investment Advisors, LLC with notifications on news.